Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more
Veracyte Inc (VCYT) - Net Assets
Latest net assets as of September 2025: $1.26 Billion USD
Based on the latest financial reports, Veracyte Inc (VCYT) has net assets worth $1.26 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.37 Billion) and total liabilities ($110.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.26 Billion |
| % of Total Assets | 91.95% |
| Annual Growth Rate | 46.07% |
| 5-Year Change | 179.17% |
| 10-Year Change | 2194.48% |
| Growth Volatility | 279.05 |
Veracyte Inc - Net Assets Trend (2011–2024)
This chart illustrates how Veracyte Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Veracyte Inc (2011–2024)
The table below shows the annual net assets of Veracyte Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.18 Billion | +12.63% |
| 2023-12-31 | $1.04 Billion | -2.89% |
| 2022-12-31 | $1.08 Billion | -1.94% |
| 2021-12-31 | $1.10 Billion | +160.31% |
| 2020-12-31 | $421.23 Million | +75.91% |
| 2019-12-31 | $239.46 Million | +200.24% |
| 2018-12-31 | $79.75 Million | +114.25% |
| 2017-12-31 | $37.23 Million | -37.52% |
| 2016-12-31 | $59.58 Million | +16.25% |
| 2015-12-31 | $51.25 Million | +23.87% |
| 2014-12-31 | $41.37 Million | -26.70% |
| 2013-12-31 | $56.44 Million | +1051.66% |
| 2012-12-31 | $4.90 Million | -42.54% |
| 2011-12-31 | $8.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Veracyte Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40256300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $78.00K | 0.01% |
| Other Comprehensive Income | $-36.09 Million | -3.07% |
| Other Components | $1.66 Billion | 140.82% |
| Total Equity | $1.18 Billion | 100.00% |
Veracyte Inc Competitors by Market Cap
The table below lists competitors of Veracyte Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Silergy Corp
TW:6415
|
$2.63 Billion |
|
Tibet Huayu Mining Co Ltd
SHG:601020
|
$2.63 Billion |
|
Steadfast Group Limited
F:1S6
|
$2.64 Billion |
|
All Winner Technology Co Ltd
SHE:300458
|
$2.64 Billion |
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
$2.63 Billion |
|
AVIC Heavy Machinery Co Ltd
SHG:600765
|
$2.63 Billion |
|
Ellington Financial Inc.
NYSE:EFC-PD
|
$2.63 Billion |
|
Plug Power Inc
NASDAQ:PLUG
|
$2.63 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Veracyte Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,044,102,000 to 1,175,966,000, a change of 131,864,000 (12.6%).
- Net income of 24,138,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 12,072,000.
- Other factors increased equity by 119,798,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $24.14 Million | +2.05% |
| Other Comprehensive Income | $-12.07 Million | -1.03% |
| Other Changes | $119.80 Million | +10.19% |
| Total Change | $- | 12.63% |
Book Value vs Market Value Analysis
This analysis compares Veracyte Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.23x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 55.72x to 2.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.60 | $33.48 | x |
| 2012-12-31 | $0.35 | $33.48 | x |
| 2013-12-31 | $13.57 | $33.48 | x |
| 2014-12-31 | $1.91 | $33.48 | x |
| 2015-12-31 | $1.98 | $33.48 | x |
| 2016-12-31 | $2.07 | $33.48 | x |
| 2017-12-31 | $1.10 | $33.48 | x |
| 2018-12-31 | $2.15 | $33.48 | x |
| 2019-12-31 | $5.19 | $33.48 | x |
| 2020-12-31 | $7.91 | $33.48 | x |
| 2021-12-31 | $16.15 | $33.48 | x |
| 2022-12-31 | $15.03 | $33.48 | x |
| 2023-12-31 | $14.37 | $33.48 | x |
| 2024-12-31 | $15.05 | $33.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Veracyte Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.41%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.11x
- Recent ROE (2.05%) is above the historical average (-66.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -169.34% | -546.12% | 0.25x | 1.23x | $-15.30 Million |
| 2012 | -380.51% | -160.38% | 0.61x | 3.89x | $-19.14 Million |
| 2013 | -45.32% | -116.89% | 0.27x | 1.41x | $-31.22 Million |
| 2014 | -70.99% | -76.91% | 0.59x | 1.57x | $-33.51 Million |
| 2015 | -65.76% | -68.08% | 0.66x | 1.47x | $-38.83 Million |
| 2016 | -52.63% | -48.18% | 0.64x | 1.70x | $-37.32 Million |
| 2017 | -83.29% | -43.09% | 0.91x | 2.11x | $-34.73 Million |
| 2018 | -28.84% | -25.00% | 0.76x | 1.51x | $-30.97 Million |
| 2019 | -5.26% | -10.47% | 0.44x | 1.15x | $-36.54 Million |
| 2020 | -8.29% | -29.71% | 0.26x | 1.09x | $-77.03 Million |
| 2021 | -6.89% | -34.42% | 0.18x | 1.08x | $-185.21 Million |
| 2022 | -3.40% | -12.33% | 0.26x | 1.08x | $-144.08 Million |
| 2023 | -7.13% | -20.61% | 0.32x | 1.07x | $-178.81 Million |
| 2024 | 2.05% | 5.41% | 0.34x | 1.11x | $-93.46 Million |
Industry Comparison
This section compares Veracyte Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Veracyte Inc (VCYT) | $1.26 Billion | -169.34% | 0.09x | $2.63 Billion |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |